VXRT - Vaxart signs pact with hVIVO to help develop oral COVID-19 vaccine pill

• Vaxart ( VXRT ) said on Thursday it had entered an agreement with hVIVO Services Limited, a subsidiary of London-based firm Open Orphan.
• Under the agreement, hVIVO will conduct a study and develop a human challenge model based on the Omicron variant of SARS-CoV-2 with the intent to conduct a subsequent Phase II Human Challenge Trial of Vaxart’s oral COVID-19 vaccine pill candidate.
• hVIVO is a contract research organization and global leader in testing infectious and respiratory disease products using HCTs.
• hVIVO will conduct a characterization study to establish a dose of the Omicron challenge virus that will cause a safe and reliable infection in healthy volunteers.
• The Omicron human challenge trial is expected to begin in 2023.

For further details see: